



ASX Announcement

1 April 2020

STATUS UPDATE ON THE 31 DECEMBER 2019 FINANCIAL STATEMENTS

Eagle Health Holdings Limited (ASX: EHH) (“Eagle” or the “Company”) wishes to inform the market that the lodgement of the Company’s audited financial statements for the year ending 31 December 2019 is unfortunately delayed. The Company’s shares were accordingly placed in suspension by the ASX from market open today.

The Company is working diligently with its auditors to obtain all supporting documents and to resolve all outstanding matters in the most timely manner. Eagle will advise the market accordingly as to the timing of the release of the audited financial statements for 31 December 2019.

Approved for release by the full Board of Directors.

-ENDS-

Contact:

Henko Vos, Company Secretary

Email: henko.vos@nexasperth.com.au

About Eagle Health Holdings Limited

Eagle is an ASX listed vertically integrated health and nutritional products business which develops, manufactures and distributes products into 26 provinces in China. Eagle has collectively more than 300 Zhang Lao San exclusive product stores and franchised stores throughout China, with a further 271 distribution partners placing Eagle’s branded products into more than 30,000 outlets across the country. Eagle produces a range of traditional Chinese Medicine and Western nutritional products including amino acids, protein supplements, lozenges and dendrobium oil. Eagle has a GMP certified manufacturing facility and a Head Office in Xiamen, China, acting as a central hub for distribution into Chinese pharmacies, health food stores, trading companies and supermarkets. Eagle has a corporate and sales office in Melbourne, Australia. Eagle has a stated strategy of acquiring or partnering with quality Australian products for distribution into China.

For more information visit: www.auehh.com.au or www.eaglehealthltd.com/EN/index.aspx